While an in vitro study with MSCs engineered to express IL2 did show conflicting results regarding tumor progression, [67], the tumor-targeted production of antitumor agents in MSCs is likely to overcome any (potential) endogenous tumor-supporting effect of MSCs in vivo. Here, IL2 is linked to neoplasm.